A cell therapy company developing programmed T cell therapies, with its lead program centered on a CD19-directed CAR-T for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
A cell therapy company developing programmed T cell therapies, with its lead program centered on a CD19-directed CAR-T for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
